SLE Clinical Trial Design and Outcome Measures

Save

Clinical trials remain a challenge in SLE and a number of outcome measures have been used with varying success.

Two abstracts in this session sought to address novel ways to assess responses in SLE trials.

Tech Tools for Rheumatologists Version 3.0

Save

Low-dose Bactrim Safe with Methotrexate in AAV

Save

A high proportion of GPA patients receive pneumocystis prophylaxis, usually with TMP-SMX (Bactrim), and drug interactions are always a concern.  

Large Vessel Vasculitis: Giant Cell Arteritis and Takayasu Arteritis

Save

Prof Weyland started by explaining that giant cell arteritis (GCA) and Takayasu Arteritis (TA) are granulomatous forms of arteritis.

Gut-derived TNF: Connection Between Crohn’s and SpA and Sacroiliitis

Save

The pathogenesis between microscopic gut inflammation leading to the development of Crohn’s disease and sacroiliitis has been poorly understood. Dr. Debusschere, et al sought to understand this important link between IBD and axial SpA.

Co-morbid Fibromyalgia

Save

Sustenance Inspector’s 2017 Annual ACR report

Save

There are two things I learned in rheumatology fellowship.

1. Never burn any bridges because everyone in rheumatology knows each other

2. Rheumatologists like their food

Podcast of ACR Day 1

Save

Check out this compilation of our ACR Day 1 videocasts merged into one 59 minute podcast !

https://soundcloud.com/rheumnow/rheumnow-acr-2017-san-diego-day-1

ACR 2017 - Day 1 Highlights

Save

Curtis and colleagues presented a plenary session that analyzed the duration of drug holidays and the risk of subsequent fractures (FX) in women starting bisphosphonates (BP).

RA and Cardiac Co-Morbidities

Save

We know that cardiovascular disease (CVD) is the leading cause of death in RA and that traditional risk factors do not fully account for increased risk.

Complementopathies: Redefining Old Diseases

Save

From Dr. Michelle Petri’s lecture on Antiphospholipid Syndrome Updates at ACR17 Review Course on Saturday, I learned that there is now a new class of diseases called the complementopathies.  This was the first time I heard of this term; how many patients did I misdiagnose who really had this and what are the ICD10 codes?!

The Red Eye in the Rheumatology Patient

Save

Professor Rosenbaum is well known for his expertise in rheumatic eye disease and he gave a great summary of how to approach your patient having a red eye.

Reactive Arthritis

Save

Prof Robert Inman gave a great summary of the state of the art in reactive arthritis (ReA).

Increasing Incidence of Paradoxical Autoimmune Disease with Biologics?

Save

With the increasing use of biologic therapies to treat rheumatic disease has come an awareness of a small but real risk of developing de novo autoimmune disease.

Romosozumab vs Alendronate in Postmenopausal Osteoporosis

Save

Poster 318 presented at the ACR on Sunday morning caught attention of many, highlighting updates in phase 3 active controlled study of romosozumab vs alendronate in patients with postmenopausal osteoporosis with high risk of fracture.

Key Takeaways from ACR Review Course

Save

The ACR Review Course was superb once again from top to bottom, from Blue Fingers to Practical Treatment of RA. Every year I wonder if I should skip it, but each year I go. And I have never regretted it. Here are my take-home messages and “pearls” from the ACR Review Course.

2018 Changes for MOC: More Options, But Is It Better?

Save

Responding to criticisms that the 10 year maintenance of certification exam is expensive, time-consuming, and not reflective of clinical practice, the American Board of Internal Medicine recently issued changes to their requirements, allowing more options for physicians to recertify.

BMS Featured Presentations from ACR 2017

Save

Bristol-Myers Squibb Company confirmed that 34 abstracts related to ORENCIA® (abatacept) and the Company’s immunoscience pipeline will be presented at the 2017 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting, November 3-8, 2017, in San Diego.

Novartis Features Secukinumab Data at ACR 17

Save

Novartis has announce it will present its long-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting

Abbvie's Robust ACR Presentations

Save

AbbVie announced that data from 38 abstracts of HUMIRA® (adalimumab) and the company's portfolio of investigational immunology medicines will be presented at the 2017 American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) Annual Meeting, November 3-8, in S